Free shipping on all orders over $ 500
Abmole Inhibitor Catalog 2017

CDK Cyclin-dependent kinase


Cat.No.  Name Information
M10347 Abemaciclib (LY2835219) Abemaciclib (LY2835219) is a potent and selective inhibitor for CDK4 and CDK6 with IC50 values of 2 nM and 10 nM, respectively.
M10327 Zotiraciclib Zotiraciclib (TG02, SB1317) is an orally bioavailable, brain penetrant multi-kinase inhibitor of CDK2, JAK2, and FLT3 with IC50 values of 13, 73, and 56 nM, respectively.
M10258 SR-4835 SR-4835 is a highly selective, dual inhibitor of CDK12 with IC50 values of 99 nM, Kd of 98 nM and CDK13 with Kd of 4.9 nM, respectively.
M10033 Trilaciclib Trilaciclib (G1T28) is a potent first-in-class reversible CDK4/6 inhibitor with IC50 of 1 nM and 4 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.
M9910 CDKI-73 CDKI-73 is a potent and orally active CDK9 inhibitor with Ki of 4 nM.
M9779 THZ531 THZ531 is a covalent CDK12 and CDK13 inhibitor with IC50 values of 158 nM and 69 nM, respectively.
M9761 AZD-5597 AZD-5597 is potent CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines.
M9755 CYC065 CYC065 (Fadraciclib) is an orally bioavailable inhibitor of cyclin dependent kinases 2 and 9 (CDK2/9) with IC50 values of 5 and 26 nM, respectively.
M9622 BAY-1143572 Racemate BAY-1143572 Racemate (Atuveciclib Racemate) is the racemate mixture of Atuveciclib, Atuveciclib is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM.
M9558 JSH-150 JSH-150 is a potent CDK9 inhibitor with IC50 of 1 nM.
M9553 PF-06873600 PF-06873600 is an orally bioavailable, cyclin-dependent kinase (CDK) inhibitor, with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively.
M9489 SY-1365 SY-1365 (Mevociclib) is a selective covalent CDK7 inhibitor.
M8995 THZ2 THZ2 (an analog of THZ1) is a potent and selective CDK7 inhibitor which overcomes the instability of THZ1 in vivo (IC50s: CDK7=13.9 nM; TNBC cells=10 nM).
M8969 LY-3177833 LY-3177833 is a potent and selective inhibitor of CDC7 with IC50 of 3.3 nM.
M8962 Voruciclib Voruciclib (P1446A-05) is a protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with IC50s of 90nM, 25nM, and 22nM for CDK4-CyclinD1, CDK1-Cyclin B, and CDK9-Cyclin T, respectively.
M8902 CVT-313 CVT-313 is a potent and selective inhibitor of CDK2 that prevents neointimal proliferation, which has an IC50 of 0.5 microM in vitro.
M8369 PNU112455A hydrochloride PNU112455A is an ATP site competetive inhibitor of CDK2 and CDK5.
M8015 Purvalanol A Purvalanol A is a potent, cell-permeable cyclin-dependent protein kinase (cdk) inhibitor.
M7557 ON123300 ON123300 is a potent inhibitor of CDK4, with an IC50 of 3.8 nM, with little inhibitory activity against CDKs 1,2,5 and 8.
M6283 SCH 900776 (CAS:891494-64-7) MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2.
M6199 MSC2530818 MSC2530818, a CDK8 inhibitor with the IC50 of 2.6 nM, displays excellent kinase selectivity, biochemical and cellular potency, microsomal stability, and is orally bioavailable.
M6167 Palbociclib Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases.
M6147 M2I-1 M2I-1 a small Mad2 inhibitor-1. the first small molecule inhibitor targeting the binding of Mad2 to Cdc20, an essential proteinprotein interaction (PPI) within the SAC.
M5332 NU2058 NU2058 is a guanine-based CDK inhibitor with IC50 of 17 μM and 26 μM for CDK2 and CDK1.
M5328 LDC000067 LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.
M5305 RO-3306 RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
M5263 LDC4297 LDC4297 is a novel CDK7 inhibitor (IC50=0.13±0.06 nM for CDK7 versus IC50s between 10 nM and 10,000 nM for all other analyzed CDKs).
M5228 THZ1 THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7.
M5029 WHI-P180 WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
M4889 Ribociclib succinate (LEE011 succinate) Ribociclib succinate (LEE011 succinate) is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
M4617 Cucurbitacin-E Cucurbitacin-E is a natural compound which from the climbing stem of Cucumic melo L, which significantly suppresses the activity of the cyclin B1/CDC2 complex.
M4393 Wogonin Wogonin is a cell-permeable and orally available flavonoid that displays anti-inflammatory and anticancer properties.
M3890 SU9516 SU9516 is a selective CDK2 inhibtor with IC50 of 22 nM which is less potent for CDK1/CDK4(IC50=40/200 nM) and has no inhibition on PKC, EGFR, p38MAPK etc.
M3774 Kenpaullone Kenpaullone is potent inhibitor of CDK1/cyclin B and GSK-3β with IC50 values of 0.4 and 0.23 μM respectively.
M3729 TAC-101 TAC-101 is a retinobenzoic acid with potential antineoplastic activity.
M3687 AT7519 hydrochloride AT7519 hydrochloride is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM and induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition.
M3641 XL413 XL413 (BMS-863233) is a potent and selective cell division cycle 7 homolog (CDC7) kinase inhibitor with IC50 of 3.4 nM.
M3519 PHA-848125 PHA-848125 is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7.
M3504 BS-181 hydrochloride BS-181 is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.
M3483 Flavopiridol hydrochloride Flavopiridol competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA.
M3475 PHA-793887 PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM. It is greater than 6-fold more selective for CDK2, 5, and 7 than CDK1, 4, and 9.
M3062 TG003 TG003 is a potent and ATP-competitive Cdc2-like kinase (Clk) inhibitor with IC50 of 20 nM, 200 nM, and 15 nM for Clk1, Clk2, and Clk4, respectively. No inhibitory effect on Clk3, SRPK1, SRPK2, or PKC.
M2913 Palbociclib Isethionate Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 2/3.
M2911 P276-00 p276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively.
M2893 NU6027 NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.
M2858 ML167 ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC50 of 136 nM, >10-fold selectivity for closely related kinases Clk1-3 and Dyrk1A/1B.
M2590 Purvalanol B Purvalanol B(NG-95) is a cyclin-dependent kinase inhibitor with IC50 values of 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively.
M2434 BAY 1000394 BAY 1000394 is an orally bioavailable pan-CDK inhibitor for CDK1/2/3/4/7/9 with IC50 of 5-25 nM. It also potently inhibits Aurora A, Clk2, ARK5, FGFR1, Flt3, and JAK2/3. Phase 1/2.
M2323 BMS-265246 BMS265246 is a potent and selective CDK inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively.
M2322 PHA-767491 PHA-767491 is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.